Knight Therapeutics gets $125mm by selling priority review voucher to Gilead
Knight Therapeutics Inc., a Paladin Labs spec pharma spin-off, raised $125mm in cash by selling its neglected tropical disease priority review voucher (PRV) to Gilead Sciences Inc. Knight put the PRV up for sale in March 2014.
- Specialty Pharmaceuticals
- Priority Review Voucher (PRV) Sale
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com